Gazi University Health Research and Application Center Gazi Hospital

Ankara 6560

6 studies enrolling now · 10 studies all time

What they study most

Active Nonsegmental Vitiligo, Advanced Non-Small Cell Lung Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Crohn's Disease, Hemophilia A, Hemophilia B, Lung Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer

Studies at this site

• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Recruiting now
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — Recruiting now
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors — Recruiting now
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling